Buflomedil

This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7I71DQ432, chemically known as 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone but generally known as buflomedil, which bears US NIH Compound Identifier 2467. Buflomedil most often comes in base and hydrochloride forms. European Medicines Agency schedules Buflomedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05963MIG. The term BUFLOMEDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules buflomedil in its Anatomical Therapeutic Chemical (ATC) Classification. BUFLOMEDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buflomedil under HS 29339990 and SITC 51577. As of Q4 2014, BUFLOMEDIL remains the US FDA Preferred Term for this commodity. Buflomedil bears US NLM identifiers UMLS ID C0054207 and NCI Concept Code C80610. SMILES: O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC.